There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX – Research Report), Corbus Pharmaceuticals (CRBP – Research Report) and Regeneron (REGN – Research Report) with bullish sentiments.
Praxis Precision Medicines (PRAX)
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Praxis Precision Medicines today and set a price target of $270.00. The company’s shares closed last Friday at $45.39.
According to TipRanks.com, Rahimi is a 4-star analyst with an average return of
Currently, the analyst consensus on Praxis Precision Medicines is a Strong Buy with an average price target of $132.00, implying a 192.0% upside from current levels. In a report issued on May 13, Robert W. Baird also maintained a Buy rating on the stock with a $117.00 price target.
See today’s best-performing stocks on TipRanks >>
Corbus Pharmaceuticals (CRBP)
In a report released today, Brian Abrahams from RBC Capital initiated coverage with a Buy rating on Corbus Pharmaceuticals and a price target of $77.00. The company’s shares closed last Friday at $45.00, close to its 52-week high of $49.87.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of
Currently, the analyst consensus on Corbus Pharmaceuticals is a Strong Buy with an average price target of $63.00, implying a 37.5% upside from current levels. In a report issued on May 8, Oppenheimer also maintained a Buy rating on the stock with a $60.00 price target.
Regeneron (REGN)
Piper Sandler analyst Christopher Raymond maintained a Buy rating on Regeneron today and set a price target of $1000.00. The company’s shares closed last Friday at $982.29, close to its 52-week high of $998.33.
According to TipRanks.com, Raymond is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Regeneron with a $1057.28 average price target, a 9.1% upside from current levels. In a report issued on May 13, Evercore ISI also initiated coverage with a Buy rating on the stock with a $1150.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PRAX:
- Praxis Precision Medicines to Participate in Upcoming Investor Conferences
- Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Praxis Precision Medicines reports Q1 EPS ($2.84), consensus ($2.08)
- Is PRAX a Buy, Before Earnings?
- Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
